Iptacopan Disease Interactions

Initiation of therapy with iptacopan is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type B. Complete or update vaccination against encapsulated bacteria at least 2 weeks before the first dose of iptacopan, according to current Advisory Committee on Immunization Practices (ACIP) recommendations for patients on complement inhibitors. Antibacterial drug prophylaxis is recommended for patients who require urgent iptacopan therapy but are not up to date with vaccines against encapsulated bacteria according to ACIP recommendations; such patients should receive these vaccines as soon as possible. Interruption of iptacopan should be considered in patients who are undergoing treatment for serious infections.

The use of iptacopan is not recommended in patients with severe liver dysfunction (Child-Pugh C). No dose adjustment is needed for patients with mild or moderate liver dysfunction (Child-Pugh A or B).

No clinically significant differences in the exposure of iptacopan were observed between patients with estimated GFR in the range of 25 to less than 90 mL/min compared to those with normal estimated GFR. No data are available in patients on dialysis.